应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01952 云顶新耀
未开盘 10-14 16:08:26
31.880
-1.120
-3.39%
最高
32.960
最低
31.200
成交量
355.41万
今开
32.960
昨收
33.000
日振幅
5.33%
总市值
112.86亿
流通市值
112.86亿
总股本
3.54亿
成交额
1.13亿
换手率
1.00%
流通股本
3.54亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
两位莫德纳老将，云顶新耀的mRNA新筹码
蓝鲸财经 · 10-14 18:47
两位莫德纳老将，云顶新耀的mRNA新筹码
异动解读｜云顶新耀盘中下跌5.03%，前期mRNA引才催化后股价回落
行情直击 · 10-14 13:51
异动解读｜云顶新耀盘中下跌5.03%，前期mRNA引才催化后股价回落
港股异动丨云顶新耀一度飙升超13%，获两位前莫德纳核心科学家加盟
格隆汇 · 10-12 15:37
港股异动丨云顶新耀一度飙升超13%，获两位前莫德纳核心科学家加盟
港股异动 | 云顶新耀(01952.HK)涨超10% 美股Moderna单日大涨14% 公司加速推mRNA全球布局
智通财经 · 10-12 09:34
港股异动 | 云顶新耀(01952.HK)涨超10% 美股Moderna单日大涨14% 公司加速推mRNA全球布局
异动解读｜云顶新耀盘中上涨8.11%，两位前莫德纳科学家加盟提速mRNA全球临床
行情直击 · 10-12 09:32
异动解读｜云顶新耀盘中上涨8.11%，两位前莫德纳科学家加盟提速mRNA全球临床
云顶新耀盘初涨超5% 公司任命两位莫德纳肿瘤疫苗科学家提速mRNA全球临床
新浪港股 · 10-09
云顶新耀盘初涨超5% 公司任命两位莫德纳肿瘤疫苗科学家提速mRNA全球临床
港股异动 | 云顶新耀(01952.HK)早盘涨超5% 公司任命两位莫德纳肿瘤疫苗科学家 提速mRNA全球临床
智通财经 · 10-09
港股异动 | 云顶新耀(01952.HK)早盘涨超5% 公司任命两位莫德纳肿瘤疫苗科学家 提速mRNA全球临床
异动解读｜云顶新耀盘中上涨5.21%，两位前莫德纳mRNA顶尖人才加盟
行情直击 · 10-09
异动解读｜云顶新耀盘中上涨5.21%，两位前莫德纳mRNA顶尖人才加盟
云顶新耀(01952)迎来两位mRNA顶尖人才加盟 加速全球创新战略落地
智通财经 · 10-09
云顶新耀(01952)迎来两位mRNA顶尖人才加盟 加速全球创新战略落地
云顶新耀更新9月股份变动月报表，股本增至3.5447亿股
公告速递 · 10-07
云顶新耀更新9月股份变动月报表，股本增至3.5447亿股
异动解读｜云顶新耀盘中下跌6.17%，创新药板块调整叠加前期获利回吐
行情直击 · 10-07
异动解读｜云顶新耀盘中下跌6.17%，创新药板块调整叠加前期获利回吐
【热门行业】光遗传学获2026年诺奖：产业仍处早期，眼科赛道临床进度领先（附相关标的）
金吾财讯 · 10-06
【热门行业】光遗传学获2026年诺奖：产业仍处早期，眼科赛道临床进度领先（附相关标的）
异动解读｜云顶新耀盘中上涨5.07%，券商上调评级至买入
行情直击 · 10-06
异动解读｜云顶新耀盘中上涨5.07%，券商上调评级至买入
创新药概念普升 歌礼制药-B（01672）涨11.78%、再鼎医药（09688）涨6.55%
金吾财讯 · 10-06
创新药概念普升 歌礼制药-B（01672）涨11.78%、再鼎医药（09688）涨6.55%
【券商聚焦】西部证券上调云顶新耀（01952）评级至买入 指耐赋康销售强劲
金吾财讯 · 10-05
【券商聚焦】西部证券上调云顶新耀（01952）评级至买入 指耐赋康销售强劲
异动解读｜云顶新耀盘中下跌5.04%，前日创新药及mRNA板块普涨后回落
行情直击 · 10-02
异动解读｜云顶新耀盘中下跌5.04%，前日创新药及mRNA板块普涨后回落
异动解读｜云顶新耀开盘下跌6.7%，报28.12港元
行情直击 · 10-02
异动解读｜云顶新耀开盘下跌6.7%，报28.12港元
港股三大指数拉升转涨
格隆汇 · 09-30
港股三大指数拉升转涨
创新药概念普涨 金斯瑞生物科技（01548）涨超10% 机构看好创新药及其产业链
金吾财讯 · 09-30
创新药概念普涨 金斯瑞生物科技（01548）涨超10% 机构看好创新药及其产业链
港股异动 | mRNA概念股涨幅居前 康希诺生物(06185)涨超17% 莫德纳mRNA新抗原疗法将亮相ESMO大会
智通财经 · 09-30
港股异动 | mRNA概念股涨幅居前 康希诺生物(06185)涨超17% 莫德纳mRNA新抗原疗法将亮相ESMO大会
加载更多
公司概况
公司名称：
云顶新耀
所属市场：
SEHK
上市日期：
--
主营业务：
云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。该公司已建立跨肾病、抗感染及自身免疫性疾病的产品管线。该公司的产品管线包括用于肾病治疗领域的耐赋康（TARPEYO）、用于治疗包括临床常见的革兰氏阴性菌、革兰氏阳性菌、厌氧菌等多重耐药菌的感染的依嘉（依拉环素）等产品。该公司在国内和国外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀","latestPrice":31.88,"timestamp":1791965306004,"preClose":33,"halted":0,"volume":3554054,"delay":0,"changeRate":-0.03393939393939397,"floatShares":354000000,"shares":354000000,"eps":-0.89,"marketStatus":"未开盘","change":-1.12,"latestTime":"10-14 16:08:26","open":32.96,"high":32.96,"low":31.2,"amount":112717848,"amplitude":0.053333,"askPrice":31.9,"askSize":9500,"bidPrice":31.88,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.175,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792027800000},"marketStatusCode":0,"adr":0,"listingDate":1602172800000,"exchange":"SEHK","adjPreClose":33,"openAndCloseTimeList":[[1791941400000,1791950400000],[1791954000000,1791964800000]],"volumeRatio":0.559551549383144,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"2675345306","title":"两位莫德纳老将，云顶新耀的mRNA新筹码","url":"https://stock-news.laohu8.com/highlight/detail?id=2675345306","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675345306?lang=zh_cn&edition=full","pubTime":"2026-10-14 18:47","pubTimestamp":1791974851,"startTime":"0","endTime":"0","summary":"云顶新耀的mRNA研发刚刚进入临床验证阶段：个性化肿瘤治疗性疫苗EVM16交出了首批人体数据，通用现货型肿瘤相关抗原疫苗EVM14正在推进临床。莫德纳的mRNA-4359编码PD-L1和IDO1相关抗原，试图诱导针对相关细胞的T细胞反应；mRNA-4106则采用多个共享肿瘤抗原的组合。云顶新耀原来需要解决的是能不能设计、递送和生产mRNA产品。云顶新耀在10月9日的公告中明确，两位新高管将推动mRNA平台在美国的临床开发，并与中国研发团队协作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1791881975734848937","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["01952","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167715552","title":"异动解读｜云顶新耀盘中下跌5.03%，前期mRNA引才催化后股价回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1167715552","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167715552?lang=zh_cn&edition=full","pubTime":"2026-10-14 13:51","pubTimestamp":1791957090,"startTime":"0","endTime":"0","summary":"10月14日，云顶新耀盘中下跌5.03%，报31.34港元，成交额8673.9万港元。公司近两个交易日股价曾因引入两位前莫德纳核心科学家、加速mRNA全球临床布局而明显走强，10月12日盘中一度涨超10%。最新公开信息仍围绕该项人事任命展开，缺乏新增利好催化，本次异动更多体现为前期事件驱动后的回落。已披露信息显示，新任高管将重点推动公司mRNA技术平台在美国的临床开发及相关业务布局，并与中国研发团队协作。公司中期实现营业收入11.48亿元，同比增长157.3%，股东应占亏损收窄至594万元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"云顶新耀盘中回落，mRNA引才催化后降温","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674822093","title":"港股异动丨云顶新耀一度飙升超13%，获两位前莫德纳核心科学家加盟","url":"https://stock-news.laohu8.com/highlight/detail?id=2674822093","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674822093?lang=zh_cn&edition=full","pubTime":"2026-10-12 15:37","pubTimestamp":1791790670,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["01952","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674784777","title":"港股异动 | 云顶新耀(01952.HK)涨超10% 美股Moderna单日大涨14% 公司加速推mRNA全球布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2674784777","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674784777?lang=zh_cn&edition=full","pubTime":"2026-10-12 09:34","pubTimestamp":1791768881,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1583","BK1574","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158662412","title":"异动解读｜云顶新耀盘中上涨8.11%，两位前莫德纳科学家加盟提速mRNA全球临床","url":"https://stock-news.laohu8.com/highlight/detail?id=1158662412","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158662412?lang=zh_cn&edition=full","pubTime":"2026-10-12 09:32","pubTimestamp":1791768778,"startTime":"0","endTime":"0","summary":"10月12日，云顶新耀盘中上涨8.11%，报32.02港元，成交额5230.07万港元。此次引才是云顶新耀加速推进mRNA全球战略的关键举措，两位新任高管将重点推动mRNA技术平台在美国的临床开发及相关业务布局，并与中国研发团队密切协作，进一步赋能mRNA技术平台的迭代升级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀上涨，莫德纳双星加盟提速mRNA临床","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674919884","title":"云顶新耀盘初涨超5% 公司任命两位莫德纳肿瘤疫苗科学家提速mRNA全球临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2674919884","media":"新浪港股","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674919884?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:49","pubTimestamp":1791510540,"startTime":"0","endTime":"0","summary":"模拟交易客户端云顶新耀盘初涨超5%。此次重磅引才，是云顶新耀加速推进mRNA全球战略的关键举措，将进一步强化云顶新耀mRNA技术平台的全球研发能力与国际合作布局。两位科学家将在云顶新耀管理层的领导下，重点推动云顶新耀mRNA技术平台在美国的临床开发及相关业务布局，并与中国研发团队密切协作，进一步赋能mRNA技术平台的进化。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-09/doc-iniuquqp7036894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1583","BK1574","159646","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674884577","title":"港股异动 | 云顶新耀(01952.HK)早盘涨超5% 公司任命两位莫德纳肿瘤疫苗科学家 提速mRNA全球临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2674884577","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674884577?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:34","pubTimestamp":1791509666,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","01952","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106873808","title":"异动解读｜云顶新耀盘中上涨5.21%，两位前莫德纳mRNA顶尖人才加盟","url":"https://stock-news.laohu8.com/highlight/detail?id=1106873808","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106873808?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:30","pubTimestamp":1791509451,"startTime":"0","endTime":"0","summary":"10月9日，云顶新耀盘中上涨5.21%，报30.26港元，成交额237.81万港元。此次任命旨在强化云顶新耀mRNA技术平台的全球研发能力与国际合作布局，重点推动mRNA技术平台在美国的临床开发及相关业务布局，并与中国研发团队密切协作。董事会主席吴以芳表示，两位资深科学家的加入将进一步强化公司的全球mRNA研发能力，助力推进自主mRNA技术平台及相关产品管线的全球临床开发，体现了公司持续汇聚全球顶尖人才、推进全球mRNA战略的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀上涨，两位前莫德纳专家加盟","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674881838","title":"云顶新耀(01952)迎来两位mRNA顶尖人才加盟 加速全球创新战略落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2674881838","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674881838?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:53","pubTimestamp":1791507195,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，10月9日，云顶新耀宣布任命Lakshmi Srinivasan博士担任高级副总裁、转化医学负责人，Brandon Coder博士担任转化科学与早期研究副总裁。此次任命将进一步强化云顶新耀mRNA技术平台的全球研发能力与国际合作布局。未来，公司将持续汇聚国际化顶尖人才，整合研发资源，加速全球创新战略落地。此次任命体现了云顶新耀持续汇聚全球顶尖人才、推进全球mRNA战略的承诺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505002.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀(01952)迎来两位mRNA顶尖人才加盟 加速全球创新战略落地","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01952","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139557366","title":"云顶新耀更新9月股份变动月报表，股本增至3.5447亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1139557366","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139557366?lang=zh_cn&edition=full","pubTime":"2026-10-07 16:41","pubTimestamp":1791362508,"startTime":"0","endTime":"0","summary":"云顶新耀于2026年10月7日披露截至2026年9月30日止的每月证券变动情况。公告显示，公司法定股本维持不变，依旧为5亿股普通股，面值每股0.0001美元，总额50000美元。公司已发行股份方面，截至8月底合计354077331股普通股，本月内新增发行389732股，期末已发行普通股合计354467063股。公司总股本截至9月末微幅增加至354467063股，股本结构相对稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174621228","title":"异动解读｜云顶新耀盘中下跌6.17%，创新药板块调整叠加前期获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1174621228","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174621228?lang=zh_cn&edition=full","pubTime":"2026-10-07 09:34","pubTimestamp":1791336879,"startTime":"0","endTime":"0","summary":"10月7日，云顶新耀盘中下跌6.17%，报28.24港元，成交额154.86万港元。消息面上，公司此前获西部证券上调评级至买入，且耐赋康销售强劲带动中期业绩扭亏，但股价在连续上涨后出现获利回吐，今日创新药板块整体走弱，康希诺生物跌6.16%、和铂医药跌5.64%，板块情绪拖累云顶新耀走势。公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司，产品管线覆盖肾病、抗感染及自身免疫性疾病领域，核心产品包括耐赋康及依嘉等。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673058257","title":"【热门行业】光遗传学获2026年诺奖：产业仍处早期，眼科赛道临床进度领先（附相关标的）","url":"https://stock-news.laohu8.com/highlight/detail?id=2673058257","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673058257?lang=zh_cn&edition=full","pubTime":"2026-10-06 18:22","pubTimestamp":1791282120,"startTime":"0","endTime":"0","summary":"诺奖落地的消息引发市场对光遗传学、脑科学相关赛道的关注。从行业发展阶段来看，光遗传学整体仍处于产业化早期，基础科研仍是核心需求，临床商业化尚未全面兑现。下游临床应用端，眼科赛道临床进度相对领先，但全行业目前尚无光遗传学产品完成全流程审批并获批上市，从临床试验到产品上市仍存在重大不确定性。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/YWU1MjY3ODMwOTg1Nzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YWU1MjY3ODMwOTg1Nzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993152","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","LU1794554557.SGD","LU0823426308.USD","LU0572944931.SGD","LU0708995153.HKD","LU0516423174.USD","LU2476274308.USD","BK1588","LU0417516902.SGD","LU0359201612.USD","LU0708995583.HKD","LU0516422440.USD","BK1191","HK0000306685.HKD","LU0181495838.USD","HK0000320264.USD","LU1720050803.USD","09969","LU0456827905.SGD","LU1688375341.USD","LU0348767384.USD","02228","09688","BK1576","LU0456846285.SGD","KURE","LU0140636845.USD","LU0819121731.USD","LU0634319403.HKD","LU0128522744.USD","LU0979878070.USD","LU0051755006.USD","IE00B0JY6N72.USD","BK1574","LU0516423091.SGD","LU0029874905.USD","LU1961090484.USD","01952","LU1242518931.SGD","01477","09926","BK1161","LU0052750758.USD","LU0043850808.USD","01548","LU0359202008.SGD","IBBQ","LU0540923850.HKD","LU0307460666.USD","LU0211977185.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109555251","title":"异动解读｜云顶新耀盘中上涨5.07%，券商上调评级至买入","url":"https://stock-news.laohu8.com/highlight/detail?id=1109555251","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109555251?lang=zh_cn&edition=full","pubTime":"2026-10-06 15:26","pubTimestamp":1791271589,"startTime":"0","endTime":"0","summary":"10月6日，云顶新耀盘中上涨5.07%，报29.86港元，成交额1624.27万港元。消息面上，西部证券发布研报上调公司评级至买入。西部证券指出，云顶新耀2026H1实现收入11.48亿元，主要来自耐赋康强劲销售增长，归母净亏损收窄至594.4万元，non-IFRS经调整利润9723.2万元，实现扭亏。此外，星必妥预计26Q3获批、乐瑞泊BLA申报已获受理、LNZ100预计27H1获批，多管线进展形成正面催化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀获券商上调买入，盘中上涨","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673734038","title":"创新药概念普升 歌礼制药-B（01672）涨11.78%、再鼎医药（09688）涨6.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673734038","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673734038?lang=zh_cn&edition=full","pubTime":"2026-10-06 09:54","pubTimestamp":1791251688,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念普涨，截至发稿，歌礼制药-B 涨11.78%，再鼎医药涨6.55%，金斯瑞生物科技涨5.30%，晶泰控股涨4.40%，中国生物制药涨3.96%，三生制药涨3.41%，药明生物涨3.16%，康方生物涨3.11%，云顶新耀涨3.10%，四环医药涨2.82%。2026ESMO已公布LBA标题，29项LBA的试验药物由中国药企原研或参与开发，涉及约20家企业，其中5项进入主席研讨会。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993103","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1574","LU1242518931.SGD","LU0359201612.USD","LU0516423091.SGD","09688","BK1141","LU2476274308.USD","ZLAB","06978","LU2778985437.USD","01672","01477","09926","LU0052750758.USD","00460","HK0000306701.USD","KURE","02228","LU0211977185.USD","LU0708995153.HKD","MEDX","IBBQ","LU0348766576.USD","02269","SG9999002463.SGD","LU0417516902.SGD","BK1191","BK1515","LU0320764243.SGD","LU0348784397.USD","LU0140636845.USD","BK1161","LU0029874905.USD","159992","LU0823426308.USD","01530","BK1521","IE00BPRC5H50.USD","LU0348827113.USD","LNGR","01548","BK4588","01952","LU0320764599.SGD","01177","LU0348735423.USD","LU0516422366.SGD","LU0029874061.USD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673870332","title":"【券商聚焦】西部证券上调云顶新耀（01952）评级至买入 指耐赋康销售强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2673870332","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673870332?lang=zh_cn&edition=full","pubTime":"2026-10-05 15:40","pubTimestamp":1791186049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 西部证券发布研报指，云顶新耀 2026H1实现收入11.48亿元，主要来自耐赋康强劲销售增长及海森生物商业化服务协议带来的服务收入；归母净亏损收窄至594.4万元，non-IFRS经调整利润9723.2万元，实现扭亏；截至2026H1现金及现金等价物及银行存款18.59亿元。星必妥预计26Q3获批，乐瑞泊BLA申报已于26M6获NMPA受理，LNZ100预计27H1获批，MT1013 III期临床已完成全部受试者入组。西部证券预计公司26-28年收入34.35/48.62/65.94亿元，同比+101.2%/41.6%/35.6%。该行调高公司评级至“买入”，前次评级为“增持”。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993039","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","01952","002673"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1174617381","title":"异动解读｜云顶新耀盘中下跌5.04%，前日创新药及mRNA板块普涨后回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1174617381","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174617381?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:32","pubTimestamp":1790904770,"startTime":"0","endTime":"0","summary":"10月2日，云顶新耀盘中下跌5.04%，报28.6港元/股，成交额158.48万港元。此前一个交易日，创新药概念及mRNA板块普涨，云顶新耀曾大涨7.72%，今日开盘即回落，板块整体承压。消息面上，9月30日mRNA概念股涨幅居前，莫德纳mRNA新抗原疗法亮相ESMO大会催化板块情绪，云顶新耀受益于其自研mRNA肿瘤疫苗EVM16管线预期获资金追捧。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"创新药板块普涨后回落，云顶新耀走低","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194945897","title":"异动解读｜云顶新耀开盘下跌6.7%，报28.12港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194945897","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194945897?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:21","pubTimestamp":1790904079,"startTime":"0","endTime":"0","summary":"10月2日，云顶新耀开盘下跌6.7%，报28.12港元/股，成交额0.0港元。此前一个交易日该股曾受创新药概念及mRNA板块普涨带动上涨7.72%，今日开盘回落。云顶新耀所在的生物科技行业中，个股表现分化：百济神州跌5.77%，三生制药跌2.23%，复宏汉霖涨0.68%，科伦博泰生物持平，荣昌生物持平，板块整体承压。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"云顶新耀开盘下挫，生物科技板块走弱","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671934224","title":"港股三大指数拉升转涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2671934224","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671934224?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:57","pubTimestamp":1790737054,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0501845795.SGD","LU0067412154.USD","LU1226288253.USD","IE00BZ08YT58.USD","LU0315179316.USD","LU1226287792.SGD","BK1521","IE00BZ08YR35.GBP","LU1993786604.SGD","LU0359202008.SGD","IE00B543WZ88.USD","IE00BZ08YS42.EUR","IE0008368742.USD","LU1226287529.USD","IE00B031HY20.USD","LU0880133367.SGD","BK1574","HK0000165453.HKD","LU1960683339.HKD","BK1191","LU1328277881.USD","LU2543165471.USD","LU0072913022.USD","LU1023057109.AUD","BK1515","BK1583","LU0359201885.HKD","LU1226287875.USD","LU2039709279.SGD","LU1807302812.USD","LU1813983027.USD","SG9999004220.SGD","LU0326950275.SGD","01276","06978","LU1226288170.HKD","KURE","01952","LU0314109678.HKD","LU1152091754.HKD","BK1161","IE00B5MMRT66.SGD","LU0140636845.USD","LU1951186391.HKD","LU0359201612.USD","IE0008369823.USD","01093","LU1008478684.HKD","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671222418","title":"创新药概念普涨 金斯瑞生物科技（01548）涨超10% 机构看好创新药及其产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2671222418","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671222418?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:35","pubTimestamp":1790735739,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念普涨，截至发稿，金斯瑞生物科技 涨10.10%，石药集团涨6.07%，云顶新耀涨5.79%，恒瑞医药涨5.18%，药明合联涨4.48%，晶泰控股涨4.06%，乐普生物涨3.52%，药明生物涨3.46%。消息面上，开源证券表示，整体上，持续看好创新药及其产业链及AI、脑机接口、生物制造等国家战略新兴产业。后续可重点跟踪ESMO临床数据、三季度订单及业绩验证和政策细则落地，积极把握优质创新药、CXO及生命科学上游调整后的配置机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992823","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226288170.HKD","01276","01952","BK1141","LU0359201885.HKD","LNGR","01548","BK1515","LU0348827113.USD","LU0039217434.USD","LU0540923850.HKD","BK1589","LU1008478684.HKD","HK0000306701.USD","LU0140636845.USD","06978","02269","LU1242518931.SGD","LU0128522744.USD","LU0029874905.USD","BK1610","LU0880133367.SGD","MEDX","IE00B0JY6N72.USD","02268","LU0307460666.USD","LU1807302812.USD","KURE","IE00BZ08YR35.GBP","LU1328277881.USD","LU0181495838.USD","LU0516422366.SGD","SG9999004220.SGD","LU0708995153.HKD","IE00BZ08YT58.USD","LU0823426480.USD","IBBQ","LU1242518857.USD","LU1813983027.USD","LU1688375341.USD","02228","BK1161","BK1521","BK1574","LU0072913022.USD","02157","LU1188198961.HKD","01093","159992","LU1880383366.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671822138","title":"港股异动 | mRNA概念股涨幅居前 康希诺生物(06185)涨超17% 莫德纳mRNA新抗原疗法将亮相ESMO大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2671822138","media":"智通财经","labels":["productRelease","conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671822138?lang=zh_cn&edition=full","pubTime":"2026-09-30 09:47","pubTimestamp":1790732842,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，mRNA概念股涨幅居前，截至发稿，康希诺生物涨16.78%，报36.32港元；云顶新耀涨4.29%，报29.18港元；思路迪医药股份涨1.94%，报2.89港元；剂泰科技-P涨1.44%，报16.22港元。值得注意的是，8月25日，康希诺生物与德普世生物签署《mRNA个性化治疗型肿瘤疫苗共同开发战略合作框架协议》。此前在mRNA领域，康希诺生物已布局mRNA 疫苗用于胶质母细胞瘤、横纹肌肉瘤及宫颈癌等适应症的研发。云顶新耀计划在2026年第四季度开展对mRNA疫苗EVM16的 IIT Ib研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","01244","BK1583","KCAI","BK1161","BK4585","BK1574","07666","VXUS","BK4588","06185","01952"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":0.1093},{"period":"1month","weight":0.1755},{"period":"3month","weight":0.0948},{"period":"6month","weight":-0.1941},{"period":"1year","weight":-0.3857},{"period":"ytd","weight":-0.1379}],"compareEarnings":[{"period":"1week","weight":0.0076},{"period":"1month","weight":-0.0242},{"period":"3month","weight":-0.0278},{"period":"6month","weight":-0.0706},{"period":"1year","weight":-0.0443},{"period":"ytd","weight":-0.0514}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。该公司已建立跨肾病、抗感染及自身免疫性疾病的产品管线。该公司的产品管线包括用于肾病治疗领域的耐赋康（TARPEYO）、用于治疗包括临床常见的革兰氏阴性菌、革兰氏阳性菌、厌氧菌等多重耐药菌的感染的依嘉（依拉环素）等产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01035},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039331},{"month":3,"riseRate":0.333333,"avgChangeRate":0.002002},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.092533},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045773},{"month":6,"riseRate":0.666667,"avgChangeRate":0.224714},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.090363},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.046758},{"month":9,"riseRate":0.5,"avgChangeRate":0.026462},{"month":10,"riseRate":0.5,"avgChangeRate":-0.010408},{"month":11,"riseRate":0.5,"avgChangeRate":0.086142},{"month":12,"riseRate":0.666667,"avgChangeRate":0.131823}],"exchange":"SEHK","name":"云顶新耀","nameEN":"EVEREST MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀,01952,云顶新耀股票,云顶新耀股票老虎,云顶新耀股票老虎国际,云顶新耀行情,云顶新耀股票行情,云顶新耀股价,云顶新耀股市,云顶新耀股票价格,云顶新耀股票交易,云顶新耀股票购买,云顶新耀股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}